The combination of the enhanced liver fibrosis and FIB‐4 scores to determine significant fibrosis in patients with nonalcoholic fatty liver disease
Alimentary Pharmacology & Therapeutics · 2023
DOI: 10.1111/apt.17472 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2023. Verfasst von Zobair M Younossi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia, USA. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Siemens Healthineers.
Abstract (Originalsprache)
Background
The presence of fibrosis in NAFLD is the most significant risk factor for adverse outcomes. We determined the cutoff scores of two non‐invasive te sts (NITs) to rule in and rule out significant fibrosis among NAFLD patients.
Methods
Clinical data and liver biopsies were used for NAFLD patients included in this analysis (2001–2020). The enhanced liver fibrosis (ELF) and FIB‐4 NITs were calculated. Liver biopsies were read by a single hematopathologist and scored by the NASH CRN criteria. Significant fibrosis was defined as stage F2–F4.
Results
There were 463 NAFLD patients included: 48 ± 13 years old, 31% male, 35% type 2 diabetes; 39% had significant fibrosis; mean ELF score was 9.0 ± 1.2, mean FIB‐4 score was 1.22 ± 1.05. Patients with significant fibrosis were older, more commonly male, had lower BMI but more components of metabolic syndrome, higher ELF and FIB‐4 ( p < 0.0001). The performance of the two NITs in identifying significant fibrosis was: AUC (95% CI) = 0.78 (0.74–0.82) for ELF, 0.79 (0.75–0.83) for FIB‐4. The combination of ELF score ≥9.8 and FIB‐4 ≥ 1.96 returned a positive predictive value of 95% which can reliably rule in significant fibrosis (sensitivity 22%, specificity >99%), while an ELF score ≤7.7 or FIB‐4 ≤ 0.30 had a negative predictive value of 95% ruling out significant fibrosis (sensitivity 98%, specificity 22%).
Conclusions
The combination of ELF and FIB‐4 may provide practitioners with easily obtained information to risk stratify patients with NAFLD who could be referred to specialists or for enrollment in clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia, USA.
- Center for Liver Disease, Department of Medicine, Inova Fairfax Medical Campus, Falls Church, Virginia, USA.
- Inova Medicine Service Line, Inova Health System, Falls Church, Virginia, USA.
- Center for Outcomes Research in Liver Diseases, Washington, District of Columbia, USA.
ORCID-Profile: Zobair M Younossi
Förderung
- Siemens Healthineers
Zitieren
APA
Younossi, Z. M., Stepanova, M., Felix, S., Jeffers, T., Younossi, E., Goodman, Z., Racila, A., Lam, B. P., & Henry, L. (2023). The combination of the enhanced liver fibrosis and FIB‐4 scores to determine significant fibrosis in patients with nonalcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17472
Vancouver
Younossi ZM, Stepanova M, Felix S, Jeffers T, Younossi E, Goodman Z, et al. The combination of the enhanced liver fibrosis and FIB‐4 scores to determine significant fibrosis in patients with nonalcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics. 2023. doi:10.1111/apt.17472
BibTeX
@article{Younossi2023,
author = {Younossi, Zobair M and Stepanova, Maria and Felix, Sean and Jeffers, Thomas and Younossi, Elena and Goodman, Zachary and Racila, Andrei and Lam, Brian P and Henry, Linda},
title = {The combination of the enhanced liver fibrosis and FIB‐4 scores to determine significant fibrosis in patients with nonalcoholic fatty liver disease},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2023},
doi = {10.1111/apt.17472}
}
EUVIMED